Abstract
This Viewpoint discusses the US Food and Drug Administration’s upcoming mandate on diversity actions plans for trial sponsors and the importance of developing accountability mechanisms to monitor those plans.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have